Biotech Startups
10,002 companies tagged Biotech, with their investors and founders.
0 investors
0 investors
Enveric Biosciences is a biotechnology company developing neuroplastogenic small-molecule drugs for neuropsychiatric and mental health disorders. It uses a proprietary discovery platform called The Psybrary to build an intellectual property portfolio of novel molecules targeting specific mental health indications.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
Epalex is a clinical-stage pharmaceutical company developing therapies for migraine and epilepsy, focused on patients who are inadequately treated by or resistant to existing drugs. Its pipeline includes EP102 for hard-to-treat migraine and EP103, a non-benzodiazepine antiseizure agent for drug-refractory epilepsy, using a proprietary delivery technology.
0 investors
0 investors
0 investors
EpiCrop Technologies applies epigenetic research to improve crop yields and resilience through natural crop vigor enhancement. The company serves agricultural breeding and crop production partners seeking higher-performing crop varieties.
0 investors
0 investors
EPIEN Medical develops a proprietary chemical desiccation-based debridement platform for treating impaired skin tissue and managing wounds, burns, and oral disease. The company serves healthcare professionals and veterinary practitioners globally.
0 investors
0 investors
0 investors
EpiVario is a biotechnology company developing small-molecule ACSS2 inhibitors that target a neuroepigenetic process involved in long-term memory formation, aimed at treating PTSD and substance use disorders. Spun out of the University of Pennsylvania's Epigenetics Institute, it develops pharmacotherapeutics for memory-related psychiatric and addiction disorders.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
Estrigenix Therapeutics is a pharmaceutical company developing first-in-class therapeutics based on estrogen biology to treat and prevent hot flashes and dementia in post-menopausal women. It aims to license its lead compounds to pharmaceutical companies after phase 2 clinical trials, offering menopause symptom relief without the breast cancer and stroke risks of traditional hormone replacement therapy.
0 investors
0 investors